Rheinmetall posts strong Q3 but cuts 2026 sales and margin outlook again
Delays on the German armed forces' Arminius Boxer programme and artillery ammunition lot tests forced a second guidance cut. Shares fell about 17%.
Düsseldorf-based Rheinmetall reported record nine-month growth but cut its 2026 outlook again. Sales for the first nine months rose 38% to EUR 8.4 billion and the operating result rose 69% to EUR 1.339 billion, for a 16.0% operating margin.
The company now expects full-year sales of about EUR 13.2 billion, down from a prior range of EUR 13.7 to 14.2 billion, and an operating margin of about 18.5%, down from about 19%. CNBC reported that shares plunged more than 17% in early trading.
Strong operations, delayed programmes
Rheinmetall said demand remains high and that its backlog (Rheinmetall Backlog, including framework agreements) reached EUR 78.0 billion at 30 September 2026, up from EUR 56.7 billion a year earlier. Nomination volume rose to EUR 19.1 billion. Operating free cash flow was EUR -1.698 billion after inventory build for targeted sales growth.
Guidance was cut because of delays on the German armed forces' Arminius project, which is in final negotiations and cannot be commissioned until next year, and delays in lot acceptance tests for artillery ammunition. CNBC noted that Arminius involves Boxer vehicles made by ARTEC, a joint venture of Rheinmetall and KNDS, and that this is the second outlook cut since August.
Segment picture
Vehicle Systems sales rose 20% to EUR 3.898 billion. Weapon and Ammunition sales rose 34% to EUR 2.705 billion. Air Defence sales rose 63% to EUR 731 million. Digital Systems sales rose 29% to EUR 1.328 billion. Naval Systems, reported separately after an acquisition completed at the end of February 2026, contributed EUR 679 million of sales in the first seven months post-deal.
CEO Armin Papperger said growth and profitability place Rheinmetall among global leaders in its sector and pointed to new capacity in the United Kingdom and Albacete, Spain. He also flagged naval order pursuit in Germany and internationally.
Market reaction
CNBC cited RBC analysts calling the announcement clearly negative and warning that bears may read it as part of a wider "new-tech versus old-tech" debate in defence. Citi called the third-quarter print strong even as the outlook overshadowed it. Year-to-date share losses were about 46% after the drop, CNBC said, following years of sharp gains after 2022.
Cash, working capital and Destinus colour
CNBC reported that Boxer-related delays would also push expected advance payments into 2027, affecting a previous cash conversion target of more than 40%, though Rheinmetall still expects positive operating free cash flow this year. The company also flagged fourth-quarter revenue delays tied to new business activities, including its partnership with Dutch defence technology firm Destinus.
Investors who bought the stock as a pure Ukraine-rearmament proxy are now pricing execution risk: factories can open in months, but national vehicle programmes and ammunition acceptance boards still move on political and testing calendars.
For European dual-use and defence-tech startups, the backlog of EUR 78 billion remains a demand signal. The share-price reaction shows that public markets will punish slipped milestones even when trailing growth stays among the strongest in European industry.
Why it matters for European founders and investors
European defence primes are central to rearmament spending, but guidance credibility now matters as much as order intake. Project timing risk on national programmes can move equity valuations overnight even when trailing growth is still exceptional. Related industrial coverage sits in our leaders section, including ArcelorMittal's Q3.
For suppliers and dual-use startups, the backlog still signals multi-year demand; the near-term lesson is that cash conversion and acceptance testing can slip even when political demand stays high.
What happens next
Rheinmetall will push to commission Arminius in 2027, clear ammunition acceptance bottlenecks, and defend the revised EUR 13.2 billion sales and 18.5% margin path while investing in new plants and capacity.
Spotted an error? Email contact@europreneursmedia.com and we'll correct it. See our corrections policy and editorial standards.
